



July 1, 2026

Perseus Proteomics Inc.

Securities Code: 4882 Growth TSE

email: ir@ppmx.com

**Notice Regarding the Results of a Clinical Study in Patients Who Participated in the Phase I
Clinical Trial of PPMX-T003 for Polycythemia Vera**

Perseus Proteomics Inc. hereby announces the results of the following clinical study conducted in patients who participated in the Phase I clinical trial of PPMX-T003 for polycythemia vera.

In the Phase I clinical trial, among the six patients who received PPMX-T003, four were confirmed to have required no phlebotomy for at least 17 months after completion of PPMX-T003 administration. Detailed data from this study are scheduled to be presented at a future medical conference.

This matter is expected to have no impact on the Company's financial results forecast for the current fiscal year. However, it is expected to contribute to enhancing the Company's corporate value over the medium to long term through future business development and other initiatives.

Overview of the Clinical Study:

Study Title: Study to Estimate the Pharmacodynamic Effects of T003 and Explore Trends in Pathological Changes Based on Changes in Clinical Laboratory Values in Participants in the PPMX-T003-CT102 Study

Principal Investigator: Tomoki Ito, M.D., Ph.D., Professor and Chair,
Department of Hematology and Oncology, Kansai Medical University Hospital

Further Information: Japan Registry of Clinical Trials (jRCT)
Clinical Research Plan Number: jRCT1050250129
URL: <https://jrct.mhlw.go.jp/latest-detail/jRCT1050250129>

End